Slide 1: Q3 FY25 Results Presentation ASX Announcement
4 November 2025 ASX ANNOUNCEMENT Q3 FY25 Results Presentation Attached are the presentation slides which will be delivered at the Q3 FY25 Results Presentation call, taking place on Wednesday, 5th November 2025, at 9:00 AM AEST. In this session we will share an update on the status and opportunity pr
Slide 2: Q3 FY25 Results
For personal use only Q3 FY25 Results 4 November 2025
Slide 3: One Company with two businesses democratizing access to medical imaging expertise
02 One Company with two businesses aimed at democratizing access to medical imaging For personal use only expertise Software Business Radiology Services Medical imaging software (RIS, Radiology services, primarily PACS, universal viewer, AI) in Colombia
Slide 4: Some Figures
03 For personal use only 8.9M +556 3.4K Imaging Installed Monthly Specialist studies year sites users Some 6.3M 26 58 Figures Users of the Partners Net Promoter patient portal Score
Slide 5: Q3 FY25 Financial Highlights
04 Q3 FY25 Financial Highlights For personal use only Q3 Revenue Annual Recurring Q3 Underlying Revenue (ARR) EBITDA3 Up 9% yoy $7.2m Up 24% yoy $36.4m Up 3% on a constant Up 12% on a constant YTD FY25 $0.9m $0.6m currency basis1 currency basis YTD Revenue Cash Debt Up 6% yoy2 $20.8m vs $2.5m at $3.
Slide 6: Progress in ARR
05 Progress in ARR For personal use only ARR AS AT 30 SEPT 2025 → $36.4m, up 24% vs pcp: → $36.4m, up 11% vs 30 Jun-25 → $11.7m from Software, down 2% vs $11.9m at 30 Jun-25; and → $24.7m from Radiology services, up 18% vs $20.9m at 30 Jun-25. (1) Constant currency basis assumes that historical resu
Slide 7: Financial turning point: positive EBITDA, stronger cash collection, lower debt
Financial turning point: positive EBITDA, 06 stronger cash collection, lower debt For personal use only What we did What it delivered • Tightened credit terms and collections • Underlying EBITDA: Q3 $0.6m; YTD discipline; focused on on-time payors. $0.9m. • Cost program in motion (AI- • Net operatin
Slide 8: Our focus right now
For personal use only Our focus right now
Slide 9: Aquila+ ready; strengthening partners scaling; pipeline
07 Aquila+ ready; strengthening partners scaling; pipeline For personal use only • Product-ready for scale: Aquila+ live across teleradiology, clinics and hospital groups (faster worklists, one-click tenant activation, 99.9% uptime). • Go-to-market discipline: strengthened partner channel, now 26 pa
Slide 10: Expand margins through pricing discipline, automation and mix
08 Expand margins through pricing discipline, automation and mix For personal use only Pricing & Terms Automatization & Portfolio Discipline Unit Cost & Mix → Apply improved terms & → AI-orchestrated → Prioritize higher-margin conditions and workflows (already software modules and segmentation. redu
Slide 11: Collections up, cash stable, debt down - discipline sustained
09 Collections up, cash stable, debt down - discipline sustained For personal use only Operating Discipline Outcomes • Enhanced credit controls, proactive • Receipts: Q3 $7.9m collections, and structured repayment arrangements where appropriate • Operating cashflow: +$1.2m in Q3; Cash $3.0m at quart
Slide 12: Aquila+: production-ready platform that lowers total cost-to-serve
Aquila+ : production-ready platform that 10 lowers total cost-to-serve For personal use only → ~40% faster worklists; → Faster from scan to → ~70% lower marginal fewer clicks ;embedded the answer: shorter report cost-to-serve per new voice; AI assistant for turn around and SaaS tenant; 1-click tenan
Slide 13: Software Business Highlights - IMEXHS
11 Software Business Highlights - IMEXHS For personal use only ➢ Pipeline strengthened despite several Q3 contracts slipping into Q4 FY25 / Q1 FY26; good traction in Mexico. ➢ Key wins/renewals: • OMNI Hospital (Ecuador) regained after displacing a competitor ($86k NARR, via Mobitelemed). • Grupo Sa
Slide 14: Radiology Services - RIMAB
12 Radiology Services - RIMAB For personal use only ➢ New contract: Oncolife (Colombia) 1-year high-complexity services; expected to contribute ~$1.4m NARR (services + software), supported by IMEXHS Enterprise RIS/PACS, Patient Portal and selected AI layers. ➢ Margin actions delivering: AI-orchestra
Slide 15: FY25 Guidance Reconfirmed
13 FY25 Guidance Reconfirmed For personal use only ➢ The Company expects to achieve the following for FY25: • Revenue $27.5m–$28.2m (up 4.0% to 6.6% vs pcp) and; • Underlying EBITDA $1.3m–$1.6m (vs $0.5m in pcp). ➢ Reconfirmed on the back of year-to-date performance and Q4 expectations.
Slide 16: Outlook & Priorities Q4 FY25 - Q1 FY26
14 Outlook & Priorities Q4 FY25 - Q1 FY26 For personal use only ➢ Scale Software: Strengthen and grow software across the region - expand Aquila+ and Enterprise cloud via a balanced mix of direct sales and high-performing partners. ➢ Pipeline & GTM: Several Q3 contracts slipped into Q4 FY25 / Q1 FY2
Slide 17: Thank You
For personal use only THANK YOU
Slide 18: Q&A
For personal use only Q&A
Slide 19: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co
Slide 20: Q3 FY25 Results
For personal use only Q3 FY25 Results 4 November 2025